6190 PhoenixBio Co.,Ltd. - Financial Results

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

6190

TSE Growth

PhoenixBio Co.,Ltd.

322

JPY

-2

(-0.62%)

Jan 7, 2:48 pm JST

2.04

USD

Jan 7, 12:48 am EST

Result

PTS

outside of trading hours

ー

Summary Chart Historical News Financial Result

Current Period Guidance

Annual

Result

Guidance History

Growth Rate

Profitability

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2021	1,013	-276	-223	-238	-73.6	0	May 14, 2021	J-GAAP
Mar, 2022	1,324	-167	-127	-387	-117.5	0	May 13, 2022	J-GAAP
Mar, 2023	2,124	508	511	493	145.2	0	May 15, 2023	J-GAAP
Mar, 2024	1,715	11	43	26	7.0	0	May 15, 2024	J-GAAP
Mar, 2025 Guidance	1,521	-253	-277	-281	-69.4	0	Nov 14, 2024	J-GAAP
YoY	-11.3%	－	－	－	－

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Mar, 2020	May 15, 2019	1,687	117	137	122	0	J-GAAP
	Nov 14, 2019	1,367	-87	-57	-59	0	J-GAAP
	May 15, 2020	1,310	-146	-125	-415	0	J-GAAP
Results	May 22, 2020	1,310	-146	-125	-415	0	J-GAAP
Mar, 2021	May 22, 2020	Available in future release
	Aug 12, 2020
	Feb 12, 2021
Results	May 14, 2021
Mar, 2022	May 14, 2021
	Nov 12, 2021
Results	May 13, 2022
Mar, 2023	May 13, 2022
	Feb 14, 2023
Results	May 15, 2023
Mar, 2024	May 15, 2023
	Nov 14, 2023
Results	May 15, 2024
Mar, 2025	May 15, 2024	2,121	214	214	201	0	J-GAAP
	Nov 14, 2024	1,521	-253	-277	-281	0	J-GAAP

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Mar, 2011	928	－	Available in future release
Mar, 2012	793	-14.5
Mar, 2013	980	+23.6
Mar, 2014	1,152	+17.6
Mar, 2015	881	-23.5
Mar, 2016	1,217	+38.1
Mar, 2017	1,228	+0.9
Mar, 2018	902	-26.5
Mar, 2019	1,228	+36.1
Mar, 2020	1,310	+6.7
Mar, 2021	1,013	-22.7
Mar, 2022	1,324	+30.7
Mar, 2023	2,124	+60.4
Mar, 2024	1,715	-19.3
Mar, 2025 Guidance	1,521	-11.3	-253	－	-277	－	-69.4	－

Fiscal Year	Revenue	Operating Profit	Operating Profit Margin	ROE	ROA	Total Asset Turnover Ratio	Adj. EPS
Mar, 2023	2,124	508	23.9	42.39	18.61	0.80	145.2
Mar, 2024	1,715	11	0.64	1.58	0.91	0.60	7.0
Mar, 2025 Guidance	1,521	-253	-17	-16.83	-11.09	0.60	-69.4

All-Time High

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	2,124	508	511	493	145.2
Fiscal Year	Mar, 2023	Mar, 2023	Mar, 2023	Mar, 2023	Mar, 2023

Second Half

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2021	687	-34	1	-257	-78.0	0	May 13, 2022	J-GAAP
Oct - Mar, 2022	989	141	108	137	40.4	0	May 15, 2023	J-GAAP
Oct - Mar, 2023	834	16	-2	-1	-0.3	0	May 15, 2024	J-GAAP
Oct - Mar, 2024 Guidance	733	-155	-154	-157	-38.8	0	Nov 14, 2024	J-GAAP
YoY	-12.1%	－	-7,600.0%	-15,600.0%	-14,255.6%

Cash Flow

Annual

Fiscal Year	Operating Profit	Fee Cash Flow	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Equivalents	Cash Ratio	Accounting Standards
Mar, 2022	-167	10	16	-6	-34	1,325	58.11	J-GAAP
Mar, 2023	508	121	277	-156	86	1,555	51.52	J-GAAP
Mar, 2024	11	36	-79	115	-244	1,384	50.98	J-GAAP

Actual Performance and Financial Trends

Accumulated Results 2nd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Apr - Sep, 2022	1,135	367	403	356	107.7	78.9	Nov 14, 2022	J-GAAP
Apr - Sep, 2023	881	-5	45	27	7.5	104.7	Nov 14, 2023	J-GAAP
Apr - Sep, 2024	788	-98	-123	-124	-30.9	ー	Nov 14, 2024	J-GAAP
YoY	-10.6%	-1,860.0%	－	－	－

Quarterly Results

Result

Growth Rate

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Oct - Dec, 2022	525	97	43	37	11.1	18.5	Feb 14, 2023	J-GAAP
Jan - Mar, 2023	464	44	65	100	29.5	9.5	May 15, 2023	J-GAAP
Apr - Jun, 2023	439	7	47	42	11.6	1.6	Aug 14, 2023	J-GAAP
Jul - Sep, 2023	442	-12	-2	-15	-4.2	-2.7	Nov 14, 2023	J-GAAP
Oct - Dec, 2023	447	35	-13	-13	-3.6	7.8	Feb 14, 2024	J-GAAP
Jan - Mar, 2024	387	-19	11	12	3.2	-4.9	May 15, 2024	J-GAAP
Apr - Jun, 2024	449	5	25	23	5.8	1.1	Aug 13, 2024	J-GAAP
Jul - Sep, 2024	339	-103	-148	-147	-36.6	-30.4	Nov 14, 2024	J-GAAP
YoY	-23.3%	-758.3%	-7,300.0%	-880.0%	-776.1%

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Oct - Dec, 2019	312	-22.8	Available in future release
Jan - Mar, 2020	477	+19.8
Apr - Jun, 2020	162	-43.8
Jul - Sep, 2020	139	-40.3
Oct - Dec, 2020	200	-35.9
Jan - Mar, 2021	512	+7.3
Apr - Jun, 2021	452	+179.0
Jul - Sep, 2021	185	+33.1
Oct - Dec, 2021	296	+48.0
Jan - Mar, 2022	391	-23.6
Apr - Jun, 2022	445	-1.5
Jul - Sep, 2022	690	+273.0
Oct - Dec, 2022	525	+77.4
Jan - Mar, 2023	464	+18.7
Apr - Jun, 2023	439	-1.3
Jul - Sep, 2023	442	-35.9
Oct - Dec, 2023	447	-14.9
Jan - Mar, 2024	387	-16.6
Apr - Jun, 2024	449	+2.3
Jul - Sep, 2024	339	-23.3	-103	-758.3	-148	-7,300.0	-36.6	-771.4

All-Time High Quarterly Results

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	690	278	290	253	76.5
Fiscal Year	Sep, 2022	Sep, 2022	Sep, 2022	Sep, 2022	Sep, 2022

Key Balance Sheet Figures

Fiscal Year	BPS	Equity Ratio	Total Asset	Equity	Retained Earnings	Interest-Bearing Debt Ratio	Announce	Accounting Standards
Mar, 2022	249.05	36.1	2,280	823	-2,103	1.26	May 13, 2022	J-GAAP
Mar, 2023	413.63	49.8	3,018	1,503	-1,610	0.17	May 15, 2023	J-GAAP
Mar, 2024	442.65	65.7	2,715	1,783	-1,584	0.27	May 15, 2024	J-GAAP
Apr - Sep, 2024	ー	65.9	2,534	1,670	-1,708	0.26	Nov 14, 2024	J-GAAP

PhoenixBio Co.,Ltd.(6190) Financial Results